{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000528","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.696910+00:00","generated_at":"2026-06-20T17:37:39.331573+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sutro STRO-002 Phase 1 shows 43.8% ORR in FolRα-selected ovarian cancer; registrational study Q2 2023","bullets":["STRO-002 (luvelta) Phase 1 dose-expansion: 43.8% ORR, median DOR 5.4 mo, median PFS 6.6 mo at 5.2 mg/kg in FolRα-selected (TPS>25%) patients.","FolRα-selected population (~80% of advanced ovarian cancer) drove benefit; unselected patients had 11.1% ORR.","Prophylactic pegfilgrastim reduced Grade 3+ neutropenia 85% (66.7% to 10%) and dose delays 60.6% at cycle 2.","Phase 2/3 registration-directed study REFRaME to start Q2 2023; potential accelerated approval based on ORR endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000528","json":"https://secwatch.observer/filing/0000950170-23-000528.json","markdown":"https://secwatch.observer/filing/0000950170-23-000528.md","text":"https://secwatch.observer/filing/0000950170-23-000528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023000528/0000950170-23-000528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017023000528/stro-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:37:39.331573+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}